NCT03246347View on ClinicalTrials.gov

A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 23, 2017

Primary Completion Date

September 1, 2022

Study Completion Date

March 31, 2028

Conditions
Prostate CancerProstate Adenocarcinoma
Interventions
DRUG

ADT+Docetaxel+Enzalutamide

combination therapy as listed above

Trial Locations (1)

28204

Levine Cancer Institute, Charlotte

Sponsors
All Listed Sponsors
collaborator

Astellas Pharma Inc

INDUSTRY

collaborator

Medivation, Inc.

INDUSTRY

lead

Wake Forest University Health Sciences

OTHER